Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

              Date of Report (date of earliest event reported): March 1, 2017

                                    CEL-SCI CORPORATION
                   (Exact name of Registrant as specified in its charter)

          Colorado                        01-11889                84-0916344
---------------------------         ---------------------      ----------------
(State or other jurisdiction        (Commission File No.)       (IRS Employer
     of incorporation)                                       Identification No.)

                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
          (Address of principal executive offices, including Zip Code)

             Registrant's telephone number, including area code: (703) 506-9460

                (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ]  Written communications  pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)

[ ]  Pre-commencement  communications  pursuant  to Rule  14d-2(b)  under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement  communications  pursuant to Rule  13e-14(c)  under the
     Exchange Act (17 CFR 240.13e-4(c))


Item 8.01   Other Events

     CEL-SCI  announced  that it has  received  the  official  minutes  from its
February 8, 2017 meeting  with the U.S.  Food and Drug  Administration  (FDA) in
regards to the partial  clinical hold placed on CEL-SCI's  Phase 3 head and neck
cancer  study.  Pursuant  to  the  partial  clinical  hold,  patients  currently
receiving study  treatments can continue to receive  treatment at the discretion
of their physicians and with their consent, and patients already enrolled in the
study will  continue to be  followed.  As of March 6, 2017,  928  patients  were
enrolled in this study.

     The purpose of the February 8, 2017 meeting with the FDA was to discuss the
issues raised by the FDA with respect to the partial clinical hold and to obtain
the FDA's input and clarification on how to address these issues.

     The Action Items for CEL-SCI to pursue per the minutes from the FDA are the

     1)   Provide an updated Investigator's  Brochure and current procedures for
          compliance with requirements under 21 CFR 312 Subpart D to address the
          partial clinical hold.

     2)   Provide a list of major protocol  deviations,  which CEL-SCI  believes
          will  affect  study  results,  and  provide a plan to  identify  major
          protocol  deviations  across  all  patients  enrolled  in the  Phase 3

      CEL-SCI is working diligently on responding to all Action Items.

     It is CEL_SCI's  belief that  addressing the Action Items listed above will
support a favorable decision by the FDA to lift the partial clinical hold. While
CEL-SCI  believes  that it  understands  the Action  Items,  it is possible that
CEL-SCI has not understood all issues involved. All of CEL-SCI's work is subject
to the FDA's review of CEL-SCI's  submission  upon its completion and may or may
not result in the lifting of the partial clinical hold.

Item 9.01   Financial Statements and Exhibits

     On March 6, 2017 CEL-SCI  issued a press  release,  attached as Exhibit 99,
concerning the receipt of the FDA's minutes of the February 8, 2017 meeting.



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date: March 6, 2017

                                       CEL-SCI CORPORATION

                                       By: /s/ Patricia B. Prichep
                                           Patricia B. Prichep
                                           Senior Vice President of Operations